{
    "clinical_study": {
        "@rank": "52169", 
        "brief_summary": {
            "textblock": "The purpose of this study is to see if it is safe to give GENEVAX-HIV, a new HIV vaccine, to\n      HIV-negative volunteers. This study will also look at how this vaccine affects the immune\n      system of these volunteers."
        }, 
        "brief_title": "Safety and Effects of Giving a New HIV Vaccine (GENEVAX-HIV) to HIV-Negative Volunteers", 
        "condition": [
            "HIV Infections", 
            "HIV Seronegativity"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "In this open-label study, volunteers are given an intramuscular injection of GENEVAX-HIV\n      vaccine using the Biojector 2000. Safety measures and immune response are assessed\n      accordingly."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        You may be eligible for this study if you:\n\n          -  Are 18 - 60 years old.\n\n          -  Are HIV-negative and in good health.\n\n          -  Are able to understand how infections such as HIV are spread.\n\n          -  Agree to use effective methods of birth control during the study.\n\n        Exclusion Criteria\n\n        You will not be eligible for this study if you:\n\n          -  Have hepatitis B or C.\n\n          -  Have any condition that may prevent you from completing the study.\n\n          -  Are allergic to bupivacaine, vaccines, or certain local anesthetics.\n\n          -  Have taken certain medications or have received certain therapies that may affect\n             your immune system.\n\n          -  Have an immune system disorder or have received therapy for an immune system\n             disorder.\n\n          -  Have been exposed to HIV within 6 months prior to study entry.\n\n          -  Have received an experimental HIV vaccine or any other experimental treatment within\n             30 days prior to study entry.\n\n          -  Have received blood transfusions within 6 months prior to study entry.\n\n          -  Abuse alcohol or drugs or have an uncontrolled psychiatric disorder.\n\n          -  Are pregnant or breast-feeding."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002231", 
            "org_study_id": "004", 
            "secondary_id": "04/400-003-04"
        }, 
        "intervention": {
            "intervention_name": "APL 400-003", 
            "intervention_type": "Biological"
        }, 
        "keyword": [
            "Injections, Intramuscular", 
            "HIV Antibodies", 
            "Immunity, Cellular", 
            "AIDS Vaccines", 
            "HIV Seronegativity", 
            "Dose-Response Relationship, Immunologic", 
            "Vaccines, DNA"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Philadelphia", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "19104"
                }, 
                "name": "Univ of Pennsylvania Med Ctr"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "GENEVAX-HIV (APL 400-003), a Candidate DNA Vaccine: A Pilot Dose Escalation Study of GENEVAX-HIV Delivered Intramuscularly Using the Biojector 2000 in HIV Seronegative Volunteers", 
        "overall_official": {
            "last_name": "RR MacGregor", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002231"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Wyeth-Lederle Vaccines", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2000"
    }, 
    "geocoordinates": {
        "Univ of Pennsylvania Med Ctr": "39.952 -75.164"
    }
}